YESCARTA (axicabtagene ciloleucel)

**Product type:** Cellular Therapy

**Active ingredient:** AXICABTAGENE CILOLEUCEL

**Strength:** 2000000 1/68mL

**Dosage form:** Suspension

**Route:** Intravenous

**Labeler:** Kite Pharma, Inc.

**Marketing category:** BLA (BLA125643)

**Pharmacologic class:** CD19 Receptor Interactions [MoA], CD19-directed Chimeric Antigen Receptor [EPC], CD19-specific Chimeric Antigen Receptor [CS], Genetically-modified Autologous T Cells [EPC], Increased T Lymphocyte Activation [PE], T Lymphocytes, Cultured, Autologous, Genetically-modified [EXT]